R Salgado
Overview
Explore the profile of R Salgado including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
105
Citations
3754
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Klein J, Tran W, Viswanathan S, Salgado R, Poortmans P, Machiels M
Clin Oncol (R Coll Radiol)
. 2025 Jan;
39:103742.
PMID: 39854781
Aim: Tumour-infiltrating lymphocytes (TILs) represent a promising cancer biomarker. Different TILs, including CD8+, CD4+, CD3+, and FOXP3+, have been associated with clinical outcomes. However, data are lacking regarding the value...
2.
Schlam I, Loi S, Salgado R, Swain S
ESMO Open
. 2025 Jan;
10(2):104120.
PMID: 39826475
Introduction: In this review, we evaluate the role of stromal tumor-infiltrating lymphocytes (sTILs) as a biomarker in human epidermal growth factor receptor 2 (HER2)-positive breast cancer, exploring the prognostic and...
3.
Janssen L, de Vries B, Janse M, van der Wall E, Elias S, Salgado R, et al.
Breast Cancer Res Treat
. 2024 Sep;
209(1):167-175.
PMID: 39285068
Purpose: In this study, we aimed to explore if the combination of tumor infiltrating lymphocytes (TILs) and change in tumor load on dynamic contrast-enhanced magnetic resonance imaging leads to better...
4.
Liefaard M, van der Voort A, van Seijen M, Thijssen B, Sanders J, Vonk S, et al.
NPJ Breast Cancer
. 2024 Apr;
10(1):29.
PMID: 38637568
Tumor-infiltrating lymphocytes (TILs) have been associated with outcomes in HER2-positive breast cancer patients treated with neoadjuvant chemotherapy and trastuzumab. However, it remains unclear if TILs could be a prognostic and/or...
5.
Agostinetto E, Buisseret L, Salgado R, Kok M, Ignatiadis M
Ann Oncol
. 2024 Mar;
35(5):409-411.
PMID: 38484973
No abstract available.
6.
de Boo L, Jozwiak K, Ter Hoeve N, van Diest P, Opdam M, Wang Y, et al.
ESMO Open
. 2024 Mar;
9(3):102923.
PMID: 38452438
Background: In the absence of prognostic biomarkers, most patients with early-stage triple-negative breast cancer (eTNBC) are treated with combination chemotherapy. The identification of biomarkers to select patients for whom treatment...
7.
Vega D, Yee L, McShane L, Williams P, Chen L, Vilimas T, et al.
Ann Oncol
. 2023 Aug;
35(1):145.
PMID: 37558578
No abstract available.
8.
Geurts V, Voorwerk L, Balduzzi S, Salgado R, Van de Vijver K, van Dongen M, et al.
Breast
. 2023 Jul;
70:76-81.
PMID: 37393645
The large majority of patients with HER2-positive metastatic breast cancer (MBC) will eventually develop resistance to anti-HER2 therapy and die of this disease. Despite, relatively high levels of stromal tumor...
9.
Tarantino P, Viale G, Press M, Hu X, Penault-Llorca F, Bardia A, et al.
Ann Oncol
. 2023 Jun;
34(8):645-659.
PMID: 37269905
Human epidermal growth factor receptor 2 (HER2)-low breast cancer has recently emerged as a targetable subset of breast tumors, based on the evidence from clinical trials of novel anti-HER2 antibody-drug...
10.
Thouvenin J, van Marcke C, Decoster L, Raicevic G, Punie K, Vandenbulcke M, et al.
ESMO Open
. 2022 Aug;
7(4):100524.
PMID: 35970014
PRECISION is an initiative from the Belgian Society of Medical Oncology (BSMO) in collaboration with several stakeholders, encompassing four programs that aim to boost genomic and clinical knowledge with the...